Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mike Ward

London, UK
Mike has been writing, analysing and commenting on the life sciences industry for more than 30 years as a journalist and investment bank analyst. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry's key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year and has appeared on the shortlist for that award on numerous occasions. When not commentating on all things pharma, Mike is engaged actively in pub quizzes, either as a competitor or a compiler. He is also a qualified FA soccer coach.
Advertisement
Set Alert for Articles By Mike Ward

Latest From Mike Ward

Experts Challenge GSK Triple Inhaled COPD Therapy Claims

While GSK and collaborators publish findings from the IMPACT trial comparing once-daily single-inhaler triple versus dual therapy in patients with COPD in NEJM, two clinicians in an accompanying editorial argue that the trial falls short of providing robust evidence for switching strategy.

Clinical Trials Research & Development

TVM Raises White Flag On Biovertis & Morphochem

Denoive acquires from TVM Capital both Biovertis and Morphochem, plus a Phase II ready antibiotic asset, for an initial 4% stake worth €900,000. Since their formation, Biovertis and Morphochem have had more than $96m invested in them.

Commercial M & A

BenevolentAI Scoops $115M For AI Drug Development

At a pre-money valuation of $2bn, BenevolentAI raises $115m to develop artificial intelligence approach that already can cut early drug development timeline by four years.

Artificial Intelligence Financing

Servier Acquires Shire Oncology Business For $2.4bn

French pharma Servier takes step to meet its strategic ambition of becoming a global player in oncology by acquiring Shire's cancer franchise for $2.4bn

M & A Commercial

Cellectis Collects $164M For Commercial CAR-T Transformation

Cellectis, the French clinical-stage biopharma focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells, will receive $164m from its underwritten offering of 5,646,000 American Depositary Shares at $31 per ADS. The lion’s share of the funds is earmarked to create the infrastructure to commercialize its immuno-oncology UCART product candidates.

Commercial ImmunoOncology

BioNTech COO Sean Marett Reveals How To Spend $270M

BioNTech AG raised $270m in a series A venture round at the start of 2018 as it pursues an ambition to create a fully integrated biopharmaceutical company. COO Sean Marett tells Scrip how the funds will be invested.

StartUps and SMEs Research and Development Strategies
See All
Advertisement
UsernamePublicRestriction

Register